Hypofibrinogenemia, which has been associated with CD19‐directed CAR T‐cell therapy in patients with LBCL,28, 29, 30 was observed at a higher rate in Cohort 3 than TRANSCEND NHL 001.6 This evidence concerns the gene CD19 and non-Hodgkin lymphoma.